Cargando…
Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study
Background: Patients with inflammatory bowel disease (IBD) and symptoms of irritable bowel syndrome (IBS) may be intolerant to fermentable carbohydrates (FODMAPs). The aim of this study was to test the feasibility of eliminating and subsequently reintroducing FODMAPs in patients with IBS symptoms as...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955641/ https://www.ncbi.nlm.nih.gov/pubmed/35334953 http://dx.doi.org/10.3390/nu14061296 |
_version_ | 1784676385958133760 |
---|---|
author | Melgaard, Dorte Sørensen, Jeanette Riis, Johannes Ovesen, Tine S. Leutscher, Peter Sørensen, Suzette Knudsen, Julie K. Bundgaard-Nielsen, Caspar Ejstrup, Jeanette Jensen, Ann-Maria Borre, Mette Krarup, Anne L. |
author_facet | Melgaard, Dorte Sørensen, Jeanette Riis, Johannes Ovesen, Tine S. Leutscher, Peter Sørensen, Suzette Knudsen, Julie K. Bundgaard-Nielsen, Caspar Ejstrup, Jeanette Jensen, Ann-Maria Borre, Mette Krarup, Anne L. |
author_sort | Melgaard, Dorte |
collection | PubMed |
description | Background: Patients with inflammatory bowel disease (IBD) and symptoms of irritable bowel syndrome (IBS) may be intolerant to fermentable carbohydrates (FODMAPs). The aim of this study was to test the feasibility of eliminating and subsequently reintroducing FODMAPs in patients with IBS symptoms as part of the IBD manifestation and to compare the severity of IBS symptoms and pain, bloating and quality of life (QoL). Methods: An eight-week randomised open-label FODMAP elimination with double-blinded, crossover provocations of FODMAP and placebo. Diet patients were on a low-FODMAP diet for eight weeks with blinded two-week provocations after two and six weeks. Questionnaires, blood and stool samples were collected. Results: Patient enrolment was challenging. Nineteen participants were included in the study. Eliminating low FODMAP for two weeks resulted in significant decreases in pain and bloating scores (p < 0.003), whereas there were no statistical differences in pain scores between diet patients and controls. Pain and bloating scores increased, returning to baseline levels after two weeks of double-blinded provocations with placebo, (p > 0.05). Conclusions: The results document the possibility of performing a randomised controlled study following the gold standard for testing food intolerance with blinding of the Low FODMAP diet. Recruitment of participants was challenging. |
format | Online Article Text |
id | pubmed-8955641 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89556412022-03-26 Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study Melgaard, Dorte Sørensen, Jeanette Riis, Johannes Ovesen, Tine S. Leutscher, Peter Sørensen, Suzette Knudsen, Julie K. Bundgaard-Nielsen, Caspar Ejstrup, Jeanette Jensen, Ann-Maria Borre, Mette Krarup, Anne L. Nutrients Article Background: Patients with inflammatory bowel disease (IBD) and symptoms of irritable bowel syndrome (IBS) may be intolerant to fermentable carbohydrates (FODMAPs). The aim of this study was to test the feasibility of eliminating and subsequently reintroducing FODMAPs in patients with IBS symptoms as part of the IBD manifestation and to compare the severity of IBS symptoms and pain, bloating and quality of life (QoL). Methods: An eight-week randomised open-label FODMAP elimination with double-blinded, crossover provocations of FODMAP and placebo. Diet patients were on a low-FODMAP diet for eight weeks with blinded two-week provocations after two and six weeks. Questionnaires, blood and stool samples were collected. Results: Patient enrolment was challenging. Nineteen participants were included in the study. Eliminating low FODMAP for two weeks resulted in significant decreases in pain and bloating scores (p < 0.003), whereas there were no statistical differences in pain scores between diet patients and controls. Pain and bloating scores increased, returning to baseline levels after two weeks of double-blinded provocations with placebo, (p > 0.05). Conclusions: The results document the possibility of performing a randomised controlled study following the gold standard for testing food intolerance with blinding of the Low FODMAP diet. Recruitment of participants was challenging. MDPI 2022-03-18 /pmc/articles/PMC8955641/ /pubmed/35334953 http://dx.doi.org/10.3390/nu14061296 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Melgaard, Dorte Sørensen, Jeanette Riis, Johannes Ovesen, Tine S. Leutscher, Peter Sørensen, Suzette Knudsen, Julie K. Bundgaard-Nielsen, Caspar Ejstrup, Jeanette Jensen, Ann-Maria Borre, Mette Krarup, Anne L. Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study |
title | Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study |
title_full | Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study |
title_fullStr | Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study |
title_full_unstemmed | Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study |
title_short | Efficacy of FODMAP Elimination and Subsequent Blinded Placebo-Controlled Provocations in a Randomised Controlled Study in Patients with Ulcerative Colitis in Remission and Symptoms of Irritable Bowel Syndrome: A Feasibility Study |
title_sort | efficacy of fodmap elimination and subsequent blinded placebo-controlled provocations in a randomised controlled study in patients with ulcerative colitis in remission and symptoms of irritable bowel syndrome: a feasibility study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955641/ https://www.ncbi.nlm.nih.gov/pubmed/35334953 http://dx.doi.org/10.3390/nu14061296 |
work_keys_str_mv | AT melgaarddorte efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy AT sørensenjeanette efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy AT riisjohannes efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy AT ovesentines efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy AT leutscherpeter efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy AT sørensensuzette efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy AT knudsenjuliek efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy AT bundgaardnielsencaspar efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy AT ejstrupjeanette efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy AT jensenannmaria efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy AT borremette efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy AT krarupannel efficacyoffodmapeliminationandsubsequentblindedplacebocontrolledprovocationsinarandomisedcontrolledstudyinpatientswithulcerativecolitisinremissionandsymptomsofirritablebowelsyndromeafeasibilitystudy |